Apolipoprotein E plays a crucial role in inhibiting chronic neurodegenerative processes. Howev-er, its impact on neurological function following diffuse brain injury is still unclear. This study was designed to evaluate the therapeutic effects and mechanisms of action of apolipoprotein E mimetic peptide on diffuse brain injury. Apolipoprotein E mimetic peptide was administered into the caudal vein of rats with diffuse brain injury before and after injury. We found that apo-lipoprotein E mimetic peptide signiifcantly decreased the number of apoptotic neurons, reduced extracellular signal-regulated kinase1/2 phosphorylation, down-regulated Bax and cytochrome c expression, decreased malondialdehyde content, and increased superoxide dismutase activity in a dose-dependent manner. These experimental ifndings demonstrate that apolipoprotein E mimetic peptide improves learning and memory function and protects against diffuse brain injury-induced apoptosis by inhibiting the extracellular signal-regulated kinase1/2-Bax mito-chondrial apoptotic pathway.

Current evidence shows that apolipoprotein E (APOE), apolipoprotein CI (APOC1) and low density lipoprotein receptor-related protein (LRP) variations are related to late-onset Alzheimer’s disease. However, it remains unclear if genetic polymorphisms in these genes are associated with cognitive decline in late-onset Alzheimer’s disease patients. We performed a 30-month longitudi-nal cohort study to investigate the relationship between Alzheimer’s disease and APOE, APOC1, and LRP. In this study, 78 Chinese Han patients with late-onset Alzheimer’s disease were recruit-ed form Guangxi Zhuang Autonomous Region in China. APOE, APOC1, and LRP genotyping was performed using polymerase chain reaction-restriction fragment length polymorphisms. The Mini-Mental State Examination and Clinical Dementia Rating Scale were used to assess pa-tients’ cognitive function. After a 30-month follow-up period, we found a signiifcant reduction in Mini-Mental State Examination total score, a higher proportion of patients fuliflling cognitive impairment progression criteria, and a higher proportion of APOC1 H2 carriers in APOEε4 carriers compared with non-carriers. In addition, the APOEε4 allele frequency was signiifcantly higher in the cognitive impairment progression group compared with the non-cognitive im-pairment progression group. In conclusion, APOEε4 plays an important role in augmenting cognitive decline, and APOC1 H2 may act synergistically with APOEε4 in increasing the risk of cognitive decline in Chinese patients with late-onset Alzheimer’s disease.

载脂蛋白E基因多态性与创伤性脑损伤后炎症反应的相关性

载脂蛋白E(apolipoprotein E,apoE代表载脂蛋白,APOE代表其基因)是血浆中重要的载脂蛋白之一,在血浆胆固醇、甘油三酯及磷脂的转运和代谢中发挥作用.